<DOC>
	<DOCNO>NCT00093041</DOCNO>
	<brief_summary>The purpose trial determine safety zalutumumab treatment head neck cancer .</brief_summary>
	<brief_title>Zalutumumab Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The study population eligible study adult male female patient good performance status histologically confirm recurrent metastatic SCCHN , amenable standard curative palliative therapy . Diagnosis squamous cell carcinoma oral cavity , nasal cavity , paranasal sinus , nasopharynx , oropharynx , hypopharynx larynx . Primary recurrent disease curative establish palliative treatment amenable WHO performance status 1 2 . Received certain treatment within 4 week prior administration study drug Previous severe allergic reaction ( e.g . angioedema , severe asthma , anaphylaxis ) . Skin disease require systemic local corticosteroid therapy . Known brain metastasis leptomeningeal disease . Signs symptom acute illness . Bacterial , fungal viral infection . Certain serious medical condition , include kidney liver disease , psychiatric illness , myocardial infarction within one year stomach , lung , heart , hormonal , nerve blood disease . Pregnant breastfeed woman . Women childbearing age unable unwilling use IUD hormonal birth control whole trial . Simultaneous participation trial involve investigational drug participate trial within 4 week prior start trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Head neck cancer</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
</DOC>